Flockerzi Elias, Daas Loay, Schlötzer-Schrehardt Ursula, Zimpfer Annette, Bohle Rainer, Seitz Berthold
Department of Ophthalmology, Saarland University Medical Center, Kirrberger Straße, 66421, Homburg, Germany.
Department of Ophthalmology, University of Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany.
Int Ophthalmol. 2019 Jun;39(6):1413-1418. doi: 10.1007/s10792-018-0954-7. Epub 2018 Jun 18.
Cystinosis is an autosomal recessive inherited lysosomal storage disease with an incidence of 1:100.000 up to 1:200.000 caused by a gene mutation of a lysosomal transport protein resulting in deposition of cystine in lysosomes in all cells and tissues. In the cornea, crystalline, gold-dust deposition of cystine leads to visual impairment, recurrent erosions, photophobia, epiphora and blepharospasmus. Standard therapy is topical and systemic application of cysteamine which may resolve the accumulated cystine crystals.
This is a case report of a thirty-one-year-old patient who already underwent renal transplantation because of nephropathic cystinosis. Visual impairment by cystine crystal deposition was aggravated by a central avascular pannus formation in his right eye. Penetrating keratoplasty was performed in intention to improve the patient's visual acuity and life quality.
After penetrating keratoplasty in the right eye, there was only a slight visual improvement. OCT scans of the macula revealed intraretinal cystine crystals and a cystoid macular edema, which was treated with a bevacizumab injection. Transmission electron microscopy of the excised cornea revealed spiky intracorneal inclusions and confocal in vivo microscopy of the left eye allowed detailed visualization of the cystine crystal deposition.
There is a variability of ocular manifestations of nephropathic cystinosis. Ophthalmologists have a central role in the early diagnosis of cystinosis as mostly the first manifestation are cystine crystals in the cornea. Penetrating keratoplasty may be one of the therapeutical options. Nevertheless, the patient has to be informed about the limited prognosis because of the persisting underlying disease.
胱氨酸病是一种常染色体隐性遗传的溶酶体贮积病,发病率为1:100000至1:200000,由溶酶体转运蛋白基因突变引起,导致胱氨酸在所有细胞和组织的溶酶体中沉积。在角膜中,胱氨酸呈结晶状、金粉尘样沉积,可导致视力损害、反复角膜糜烂、畏光、流泪和眼睑痉挛。标准治疗方法是局部和全身应用半胱胺,它可以溶解积聚的胱氨酸晶体。
本文报告一例31岁因肾病性胱氨酸病已接受肾移植的患者。右眼中央无血管性血管翳形成加重了胱氨酸晶体沉积所致的视力损害。为提高患者视力和生活质量,实施了穿透性角膜移植术。
右眼穿透性角膜移植术后,视力仅略有改善。黄斑区的光学相干断层扫描显示视网膜内有胱氨酸晶体和黄斑囊样水肿,通过玻璃体内注射贝伐单抗进行治疗。切除角膜的透射电子显微镜检查显示角膜内有尖刺状包涵体,左眼共焦活体显微镜检查可详细观察胱氨酸晶体沉积情况。
肾病性胱氨酸病的眼部表现具有多样性。眼科医生在胱氨酸病的早期诊断中起着核心作用,因为大多数情况下,最早的表现是角膜中的胱氨酸晶体。穿透性角膜移植术可能是治疗选择之一。然而,由于潜在疾病持续存在,必须告知患者预后有限。